Literature DB >> 8396526

Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci.

A Louie1, A L Baltch, W J Ritz, R P Smith, M Asperilla.   

Abstract

The in vitro inhibitory and bactericidal activities of daptomycin and reference antibiotics were determined by serial macrobroth dilution for 23 gentamicin-susceptible (MIC: < 2,000 mg/l) and 21 high-level-gentamicin-resistant (HLGR) Enterococcus faecalis, Enterococcus faecium, and Enterococcus avium isolates. The activities of daptomycin, vancomycin, and teicoplanin were independent of the gentamicin susceptibility profile and species tested. For all the isolates, the inhibitory activity of daptomycin (MIC90: 2 mg/l) was comparable to vancomycin (MIC90: 2 mg/l), but less than that of teicoplanin (MIC90: 0.5 mg/l). Daptomycin demonstrated excellent bactericidal activity against all enterococci tested (MBC90: 8 mg/l). In contrast, all microorganisms were tolerant to vancomycin and teicoplanin. Ampicillin and ciprofloxacin MICs and MBCs were dependent on enterococcal gentamicin resistance profile and species, with MICs and MBCs that ranged between 1 and > 64 mg/l. By time-kill curves, the combination of daptomycin plus ampicillin demonstrated synergistic bactericidal activity against gentamicin-susceptible and HLGR E. faecalis. Daptomycin, singly and in combination, may be useful in treating enterococcal infections, including those caused by HLGR microorganisms.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396526     DOI: 10.1159/000239141

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  7 in total

1.  Resistance studies with daptomycin.

Authors:  J A Silverman; N Oliver; T Andrew; T Li
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  In vitro activities of a new lipopeptide, HMR 1043, against susceptible and resistant gram-positive isolates.

Authors:  Pascale Bemer; Marie-Emmanuelle Juvin; Andre Bryskier; Henri Drugeon
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

3.  Activity of daptomycin with or without 25 percent ethanol compared to combinations of minocycline, EDTA, and 25 percent ethanol against methicillin-resistant Staphylococcus aureus isolates embedded in biofilm.

Authors:  R Estes; J Theusch; A Beck; D Pitrak; Kathleen M Mullane
Journal:  Antimicrob Agents Chemother       Date:  2013-02-12       Impact factor: 5.191

4.  Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients.

Authors:  Debra D Poutsiaka; Serena Skiffington; Kenneth B Miller; Susan Hadley; David R Snydman
Journal:  J Infect       Date:  2006-12-26       Impact factor: 6.072

5.  Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.

Authors:  A Louie; P Kaw; W Liu; N Jumbe; M H Miller; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

6.  Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.

Authors:  Barry H Dvorchik; David Brazier; Michael F DeBruin; Robert D Arbeit
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

7.  Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.

Authors:  Theodoros Kelesidis; Romney Humphries; Daniel Z Uslan; David A Pegues
Journal:  Clin Infect Dis       Date:  2011-01-15       Impact factor: 20.999

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.